Investors
ImmunoPrecise’s proprietary technologies and products are positioned on the leading edge of antibody development, innovating our industry as a single source provider of the full complement of antibody discovery platforms. As an investor in ImmunoPrecise Antibodies, you’re joining us at the forefront of new, exciting, and valuable advancements in next-generation antibody discovery.
ImmunoPrecise Antibodies Ltd. Stock Information
For more information, please review our Stock Quotes and Charts, Investor Presentation or visit our News Releases page.
For more information, please review our Stock Quotes and Charts, Investor Presentation or visit our News Releases page.
For more information, please review our Stock Quotes and Charts, Investor Presentation or visit our News & Releases page.
Financial Statements
Please find our financials on Sedar in English and Français.Analyst Coverage
Download March 17, 2022 Report Download March 10, 2022 Report Download December 14, 2021 Report Download November 26, 2021 Report Download October 25, 2021 Report Robert Wasserman +1 (212) 312-6764 rwasserman@benchmarkcompany.comImmunoPrecise Newsletter
Check out our most recent blog post:SARS-CoV-2-targeting monoclonal antibody therapies: A complementary strategy to vaccination.Earnings Call
The Company held an earnings conference call via webcast on March 16th, 2022. View a recording of the earnings call or view the transcript.Sign Up for
Email Alerts
Enter your email to receive financial information by email.
Eligible French companies involved with us in research and development may receive a tax credit. Learn More.